Abstract
IgE antibodies against the allergen Ara-h2 can cause life-threatening anaphylaxis upon exposure to peanuts. Desensitization strategies aim at inducing IgG responses against Ara-h2 which may compete with anaphylactogenic IgE. Here we assessed anti-Ara-h2 titers in an unselected cohort of 24,536 adult patients admitted to a general hospital for disparate medical reasons. Surprisingly, adult (n=177) and pediatric (n=76) patients with cystic fibrosis (pwCF) had IgG4, but not IgE, against several peanut and soybean allergens, yet did not suffer from peanut allergy. Antibody repertoires were not globally perturbed in pwCF, and heterozygous Cystic Fibrosis Transmembrane Regulator (CFTR) mutation carriers had the same prevalence of food allergies as pwCF. Peanut sensitisation of Cftr-/- mice failed to induce IgE and was associated with elevated IFN-γ. We conclude that CFTR is a key regulator of anaphylactogenic and tolerogenic responses to food allergens. CFTR-controlled cytokine responses including IFN-γ, in combination with a compromised epithelial barrier, may trigger a preferential IgG4 response resulting in tolerance to food allergens.
Highlights
We investigated serum IgG against Ara-h2 in 24,536 patients and identified 133 seropositives.
Seropositivity was associated with cystic fibrosis, and these patients had IgG4 but not IgE.
We reproduced these results in a paediatric validation cohort and in a Cftr-/- mouse model.
A compromised epithelial barrier and the cytokine milieu might explain this phenotype.
Competing Interest Statement
AA is a member of the clinical and scientific advisory board of Fluidic Analytics and member of the board of directors of Mabylon AG and AB2Bio AG. AA has formerly been a scientific advisor to Mabylon AG. TPJK is a member of the board of directors of Fluidic Analytics. RM and MS are employed by Cellerys AG. All authors declare no competing interests.
Funding Statement
Grants of the Swiss Personalized Health Network (Driver Grant 2017DRI17), of the Swiss National Science Foundation (SNF; grant #179040), of the Innovation Fund of the University Hospital Zurich (INOV00096), of the NOMIS Foundation, the Schwyzer Winiker Stiftung, and the Baugarten Stiftung (coordinated by the USZ Foundation, USZF27101) were awarded to AA and ME.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethikkommission Kanton Zuerich of University of Zurich gave ethical approval for this work. The Yale IRB of Yale Medical School gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes